These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
662 related articles for article (PubMed ID: 24334116)
1. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy. Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116 [TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model. Macedo MF; Quinta R; Pereira CS; Sa Miranda MC Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450 [TBL] [Abstract][Full Text] [Related]
4. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233 [TBL] [Abstract][Full Text] [Related]
5. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy. Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537 [TBL] [Abstract][Full Text] [Related]
6. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease. Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients. Tsuboi K; Yamamoto H BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315 [TBL] [Abstract][Full Text] [Related]
8. An in vitro model of Fabry disease. Shu L; Murphy HS; Cooling L; Shayman JA J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856 [TBL] [Abstract][Full Text] [Related]
9. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053 [TBL] [Abstract][Full Text] [Related]
10. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates. Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639 [TBL] [Abstract][Full Text] [Related]
11. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298 [TBL] [Abstract][Full Text] [Related]
12. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789 [TBL] [Abstract][Full Text] [Related]
13. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients. Shiga T; Tsukimura T; Kubota T; Togawa T; Sakuraba H Intern Med; 2024 Jun; 63(11):1531-1537. PubMed ID: 37866916 [TBL] [Abstract][Full Text] [Related]
14. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180 [TBL] [Abstract][Full Text] [Related]
15. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680 [TBL] [Abstract][Full Text] [Related]
16. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096 [TBL] [Abstract][Full Text] [Related]
17. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease. Boutin M; Auray-Blais C Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980 [TBL] [Abstract][Full Text] [Related]
18. Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease. Pereira EM; do Monte SJ; do Nascimento FF; de Castro JA; Sousa JL; Filho HC; da Silva RN; Labilloy A; Monte Neto JT; da Silva AS Gene; 2014 Feb; 536(1):118-22. PubMed ID: 24334114 [TBL] [Abstract][Full Text] [Related]
19. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model. Mattocks M; Bagovich M; De Rosa M; Bond S; Binnington B; Rasaiah VI; Medin J; Lingwood C FEBS J; 2006 May; 273(9):2064-75. PubMed ID: 16724420 [TBL] [Abstract][Full Text] [Related]
20. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity. Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]